MX2022007993A - Compuesto de piridazinil-tiazolcarboxamida. - Google Patents
Compuesto de piridazinil-tiazolcarboxamida.Info
- Publication number
- MX2022007993A MX2022007993A MX2022007993A MX2022007993A MX2022007993A MX 2022007993 A MX2022007993 A MX 2022007993A MX 2022007993 A MX2022007993 A MX 2022007993A MX 2022007993 A MX2022007993 A MX 2022007993A MX 2022007993 A MX2022007993 A MX 2022007993A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- pyridazinyl
- compound
- thiazolecarboxamide compound
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se proporciona un compuesto útil como principio activo de una composición farmacéutica para el tratamiento del cáncer relacionado con la activación de células inmunitarias o el cáncer que ofrece resistencia a un tratamiento con anticuerpos anti-PD-1/anticuerpos anti-PD-L1. Los inventores de la presente han realizado estudios sobre un compuesto útil como principio activo de una composición farmacéutica para el tratamiento del cáncer relacionado con la activación de células inmunitarias o del cáncer que ofrece resistencia a un tratamiento con anticuerpos anti-PD-1/anticuerpos anti-PD-L1 y descubrieron que un compuesto de piridazinil-tiazolcarboxamida tiene efecto inhibitorio sobre DGK ? (DGKzeta), lo que da lugar a la consecución de la presente invención. El compuesto de piridazinil-tiazolcarboxamida de la presente invención tiene efecto inhibitorio sobre DGK ? y puede usarse como agente terapéutico para el tratamiento del cáncer relacionado con la activación de células inmunitarias o del cáncer que ofrece resistencia a un tratamiento con anticuerpos anti-PD-1/anticuerpos anti-PD-L1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019233673 | 2019-12-25 | ||
| PCT/JP2020/048337 WO2021132422A1 (ja) | 2019-12-25 | 2020-12-24 | ピリダジニルチアアゾールカルボキシアミド化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007993A true MX2022007993A (es) | 2022-07-21 |
Family
ID=76574296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007993A MX2022007993A (es) | 2019-12-25 | 2020-12-24 | Compuesto de piridazinil-tiazolcarboxamida. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220315603A1 (es) |
| EP (1) | EP4083038B1 (es) |
| JP (1) | JP6948659B1 (es) |
| KR (1) | KR20220119702A (es) |
| CN (3) | CN115626919A (es) |
| AR (1) | AR120896A1 (es) |
| AU (1) | AU2020413997A1 (es) |
| BR (1) | BR112022012637A2 (es) |
| CA (1) | CA3165889A1 (es) |
| CL (1) | CL2022001752A1 (es) |
| CO (1) | CO2022009124A2 (es) |
| CR (1) | CR20220328A (es) |
| DO (1) | DOP2022000137A (es) |
| EC (1) | ECSP22057324A (es) |
| IL (1) | IL294136A (es) |
| JO (1) | JOP20220163A1 (es) |
| MX (1) | MX2022007993A (es) |
| PE (1) | PE20230163A1 (es) |
| TW (3) | TW202413375A (es) |
| WO (1) | WO2021132422A1 (es) |
| ZA (1) | ZA202207543B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3165735A1 (en) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
| AR120896A1 (es) * | 2019-12-25 | 2022-03-30 | Astellas Pharma Inc | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz |
| KR20230005247A (ko) | 2020-04-24 | 2023-01-09 | 바이엘 악티엔게젤샤프트 | 면역 활성화를 위한 dgk제타 억제제로서의 치환된 아미노티아졸 |
| CN116528864A (zh) | 2020-11-30 | 2023-08-01 | 安斯泰来制药株式会社 | 杂芳基甲酰胺化合物 |
| US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP2024524210A (ja) | 2021-06-23 | 2024-07-05 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| AU2022297373A1 (en) | 2021-06-23 | 2024-01-04 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN114621214B (zh) * | 2022-04-25 | 2024-04-26 | 宜春学院 | 一种抗菌席夫碱n-酰化物及其制备方法和应用 |
| US20240217989A1 (en) * | 2022-11-18 | 2024-07-04 | Incyte Corporation | Heteroaryl Fluoroalkenes As DGK Inhibitors |
| US20240270739A1 (en) * | 2023-01-12 | 2024-08-15 | Incyte Corporation | Heteroaryl Fluoroalkenes As DGK Inhibitors |
| WO2024165470A1 (en) | 2023-02-06 | 2024-08-15 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors |
| WO2024199387A1 (zh) * | 2023-03-30 | 2024-10-03 | 微境生物医药科技(上海)有限公司 | 作为DGKζ抑制剂的化合物 |
| WO2024208198A1 (zh) * | 2023-04-06 | 2024-10-10 | 微境生物医药科技(上海)有限公司 | 作为DGKζ抑制剂的噻唑类化合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7381401B2 (en) * | 2004-01-08 | 2008-06-03 | The University Of Chicago | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase |
| TWI422376B (zh) * | 2005-01-25 | 2014-01-11 | Synta Pharmaceuticals Corp | 用於炎症及免疫相關用途之化合物 |
| JP2009524677A (ja) * | 2006-01-25 | 2009-07-02 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物 |
| US8163746B2 (en) * | 2006-04-19 | 2012-04-24 | Astellas Pharma Inc. | Azolecarboxamide derivative |
| AU2007314342B2 (en) * | 2006-10-31 | 2013-02-21 | Merck Sharp & Dohme Corp. | Anilinopiperazine Derivatives and methods of use thereof |
| LT3814348T (lt) * | 2018-06-27 | 2023-10-10 | Bristol-Myers Squibb Company | Pakeistieji naftiridinono junginiai, naudotini kaip t ląstelių aktyvatoriai |
| AR120896A1 (es) * | 2019-12-25 | 2022-03-30 | Astellas Pharma Inc | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz |
| CN116528864A (zh) * | 2020-11-30 | 2023-08-01 | 安斯泰来制药株式会社 | 杂芳基甲酰胺化合物 |
-
2020
- 2020-12-23 AR ARP200103641A patent/AR120896A1/es unknown
- 2020-12-24 BR BR112022012637A patent/BR112022012637A2/pt unknown
- 2020-12-24 IL IL294136A patent/IL294136A/en unknown
- 2020-12-24 TW TW112145679A patent/TW202413375A/zh unknown
- 2020-12-24 JO JOP/2022/0163A patent/JOP20220163A1/ar unknown
- 2020-12-24 JP JP2021531562A patent/JP6948659B1/ja active Active
- 2020-12-24 CA CA3165889A patent/CA3165889A1/en active Pending
- 2020-12-24 AU AU2020413997A patent/AU2020413997A1/en active Pending
- 2020-12-24 CR CR20220328A patent/CR20220328A/es unknown
- 2020-12-24 CN CN202211308277.1A patent/CN115626919A/zh active Pending
- 2020-12-24 EP EP20906466.6A patent/EP4083038B1/en active Active
- 2020-12-24 US US17/427,426 patent/US20220315603A1/en active Pending
- 2020-12-24 PE PE2022001161A patent/PE20230163A1/es unknown
- 2020-12-24 TW TW112145680A patent/TW202413376A/zh unknown
- 2020-12-24 CN CN202080011114.XA patent/CN113365994B/zh active Active
- 2020-12-24 KR KR1020227025714A patent/KR20220119702A/ko unknown
- 2020-12-24 TW TW109146029A patent/TW202136275A/zh unknown
- 2020-12-24 CN CN202211308268.2A patent/CN115590854B/zh active Active
- 2020-12-24 WO PCT/JP2020/048337 patent/WO2021132422A1/ja active Application Filing
- 2020-12-24 MX MX2022007993A patent/MX2022007993A/es unknown
-
2022
- 2022-06-24 DO DO2022000137A patent/DOP2022000137A/es unknown
- 2022-06-24 CL CL2022001752A patent/CL2022001752A1/es unknown
- 2022-06-30 CO CONC2022/0009124A patent/CO2022009124A2/es unknown
- 2022-07-07 ZA ZA2022/07543A patent/ZA202207543B/en unknown
- 2022-07-21 EC ECSENADI202257324A patent/ECSP22057324A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP22057324A (es) | 2022-08-31 |
| CN113365994A (zh) | 2021-09-07 |
| AU2020413997A1 (en) | 2022-06-09 |
| TW202136275A (zh) | 2021-10-01 |
| CN115590854A (zh) | 2023-01-13 |
| WO2021132422A1 (ja) | 2021-07-01 |
| KR20220119702A (ko) | 2022-08-30 |
| CA3165889A1 (en) | 2021-07-01 |
| EP4083038A4 (en) | 2023-12-20 |
| DOP2022000137A (es) | 2022-11-30 |
| IL294136A (en) | 2022-08-01 |
| US20220315603A1 (en) | 2022-10-06 |
| PE20230163A1 (es) | 2023-02-01 |
| CN115590854B (zh) | 2024-06-07 |
| EP4083038B1 (en) | 2024-10-30 |
| AR120896A1 (es) | 2022-03-30 |
| CO2022009124A2 (es) | 2022-07-19 |
| TW202413376A (zh) | 2024-04-01 |
| BR112022012637A2 (pt) | 2022-09-06 |
| ZA202207543B (en) | 2023-12-20 |
| CL2022001752A1 (es) | 2023-03-10 |
| JOP20220163A1 (ar) | 2023-01-30 |
| EP4083038A1 (en) | 2022-11-02 |
| TW202413375A (zh) | 2024-04-01 |
| JP6948659B1 (ja) | 2021-10-13 |
| CN115626919A (zh) | 2023-01-20 |
| CN113365994B (zh) | 2024-08-09 |
| JPWO2021132422A1 (ja) | 2021-12-23 |
| CR20220328A (es) | 2022-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007993A (es) | Compuesto de piridazinil-tiazolcarboxamida. | |
| MX2023006318A (es) | Compuesto de heteroarilcarboxamida. | |
| MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
| MX2020008777A (es) | Inmunoterapias relacionadas con el microbioma. | |
| SG11201907038WA (en) | Quinazoline compound | |
| EA202190630A1 (ru) | Способы комбинированной терапии | |
| PH12019502132A1 (en) | Combination therapy for the treatment or prevention of tumours | |
| WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
| PH12017502270A1 (en) | Combination therapy for the treatment of cancer | |
| MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
| MX2021002805A (es) | Terapias de combinacion. | |
| AU2017293423A8 (en) | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer | |
| MX2021000726A (es) | Terapia combinada de gen de activacion de linfocitos 3(lag-3) para el tratamiento del cancer. | |
| MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
| MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
| MX2024006094A (es) | Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer. | |
| SA523450286B1 (ar) | مركب 4-أمينو كوينازولين | |
| EA202191358A1 (ru) | Новые соединения и их применение в лечении | |
| MX2022015813A (es) | 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1. | |
| ZA202202243B (en) | Aqueous pharmaceutical composition of anti-pd1 antibody prolgolimab and the use thereof | |
| MX2021008658A (es) | Formas sólidas del inhibidor de la tirosina treonina cinasa (ttk). | |
| MX2019003374A (es) | Composicion combinada para prevenir o tratar cancer que comprende un derivado de benzofenona tiazol como un vda e inhibidor de topoisomerasa. | |
| MX2024005928A (es) | 2-amino-but-3-enamidas macrociclicas como inhibidores de mcl-1. | |
| MX2023007297A (es) | 3-fluoro-but-3-enamidas ramificadas macrociclicas como inhibidores de mcl-1. | |
| MX2022015005A (es) | Derivados de 7-pirazol-5-il-indol macrociclicos como inhibidores de mcl-1. |